The collaboration will leverage the University of Florida’s Clinical and Translational Science Institute (CTSI) Biorepository, which contains a diverse collection of normal and diseased human tissues and may be used for IRB-approved research. In addition, UF’s Southeast Center for Integrated Metabolomics (SECIM) will provide state-of the-art metabolic profiling using the IROA protocol as a foundation for exploring liver biochemical diversity and disease response.
Felice de Jong, CEO of IROA Technologies, stated, “We are pleased to be both a partner at SECIM where clients can send IROA samples for metabolic profiling analysis and now a collaborator within CTSI for biomarker discovery. We are thrilled to be working with two such significant units within the University of Florida. We feel this strength will assure a high probability of success. ”
IROA Technologies and UF will focus on analyzing and validating clinical tissue biomarkers in liver cancer and fatty liver disease, de Jong said, adding that UF will provide medical support and interpretation of results through an established expert liver disease and mass spectrometry Advisory Committee. Beyond the initial discovery phases, the ability of CTSI and SECIM to support all levels of validation and testing will be critical to the long-term success of this endeavor.
"The partnership with IROA Technologies and Dr. Chris Beecher will allow UF to develop novel methods for the identification of biomarkers for human disease. UF and the CTSI are now uniquely positioned to advance and translate metabolomics to improve health for millions of Americans," said David R. Nelson, M.D., an assistant vice president for research at UF and director of the UF CTSI. "The relationship between IROA Technologies and SECIM keeps us at the cutting edge of new and powerful metabolomics technologies,” said Art Edison, Ph.D., Director of SECIM.
Financial and other terms of the agreement were not disclosed.